用于治疗复发或难治性多发性骨髓瘤成人患者,既往经过至少3线治疗后进展(至少使用过一种蛋白酶体抑制剂及免疫调节剂)。
Peking University People's Hospital, Beijing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.